Eyeworld Daily News

2017 ASCRS Los Angeles Daily Wednesday-Ezine

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: http://daily.eyeworld.org/i/827793

Contents of this Issue


Page 13 of 27

13 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, Los Angeles 2017 Ireland), Xiidra (lifitegrast, Shire, Lexington, Massachusetts), and the TrueTear Neurostimulator (Allergan). FDA trials found that lifitegrast can work within 2 weeks, whereas previous dry eye therapy took 2 to 3 months to provide results. Meanwhile, TrueTear stimu- lates the lacrimal nerve to increase lacrimal secretions, mucin from the goblet cells, and meibomian gland secretions. Among other treatments is the LipiFlow Thermal Pulsation System (TearScience, Morrisville, North Car- olina) for meibomian gland dysfunc- tion. Dr. Holland noted the device treats the primary cause of evapora- tive dry eye-obstructed meibomian glands and urged ophthalmologists to move it up from a last-line ther- apy to first-line therapy among dry eye patients looking to have cataract surgery. "I used to hold it for when everything else failed, but now I'm offering patients the option earli- er," said Richard Lindstrom, MD, Minneapolis. Dr. Donnenfeld hailed the pipe- line of dry eye drugs and devices, in- cluding mucus-penetrating particle technology (Kala Pharmaceuticals, Waltham, Massachusetts). EW Editors' note: Dr. Donnenfeld has fi- nancial interests with Kala Pharmaceu- ticals and other companies. Dr. Holland has financial interests with TearLab and other companies. Dr. Lindstrom has financial interests with Ocular Therapeutix (Bedford, Massachusetts) and other companies. Hope for dry eye has come with the surge of recent approvals of treatments by the U.S. Food and Drug Administration: Restasis Multi- dose (cyclosporine, Allergan, Dublin, Mesa, California) is effective for ex- amining tear breakup time. Research has found that an overwhelming majority of dry eye patients had at least one component of MGD. Dr. Donnenfeld shares why it's important to diagnose dry eye before cataract surgery. INDICATIONS AND USAGE PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-infl ammatory drug (NSAID) indicated for the treatment of postoperative infl ammation and reduction of ocular pain in patients who have undergone cataract surgery. IMPORTANT SAFETY INFORMATION ABOUT PROLENSA ® • PROLENSA ® contains sodium sulfi te, a sulfi te that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in non-asthmatic people. • All topical nonsteroidal anti-infl ammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs. • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. • PROLENSA ® should not be instilled while wearing contact lenses. The preservative in PROLENSA ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA ® . • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber infl ammation, foreign body sensation, eye pain, photophobia, and blurred vision. Please see brief summary of full Prescribing Information for PROLENSA ® on adjacent page. References: 1. PROLENSA Prescribing Information, April 2013. 2. Data on fi le, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affi liates. © Bausch & Lomb Incorporated. All rights reserved. Printed in USA. PRA.0188.USA.15 The PROLENSA ® Effect POWERED FOR PENETRATION Advanced Formulation to Facilitate Corneal Penetration 1-3 pH e ffect Hal og en a ti on e ffect PROLENSA ® delivers potency and corneal penetration with QD dosing at a low concentration 1-3

Articles in this issue

Archives of this issue

view archives of Eyeworld Daily News - 2017 ASCRS Los Angeles Daily Wednesday-Ezine